List of Tables
    Table 1. Targeted Drugs for Multiple Myeloma Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Targeted Drugs for Multiple Myeloma Market Trends
    Table 3. Targeted Drugs for Multiple Myeloma Market Drivers
    Table 4. Targeted Drugs for Multiple Myeloma Market Challenges
    Table 5. Targeted Drugs for Multiple Myeloma Market Restraints
    Table 6. Global Targeted Drugs for Multiple Myeloma Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Targeted Drugs for Multiple Myeloma Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Targeted Drugs for Multiple Myeloma Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Targeted Drugs for Multiple Myeloma Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Targeted Drugs for Multiple Myeloma Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Targeted Drugs for Multiple Myeloma Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Targeted Drugs for Multiple Myeloma Revenue Share by Player, 2017-2022
    Table 13. Global Targeted Drugs for Multiple Myeloma Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Targeted Drugs for Multiple Myeloma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2021)
    Table 15. Top Players of Targeted Drugs for Multiple Myeloma in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Targeted Drugs for Multiple Myeloma Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Targeted Drugs for Multiple Myeloma Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Targeted Drugs for Multiple Myeloma Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Targeted Drugs for Multiple Myeloma Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Targeted Drugs for Multiple Myeloma Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Targeted Drugs for Multiple Myeloma Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Targeted Drugs for Multiple Myeloma Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Targeted Drugs for Multiple Myeloma Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Targeted Drugs for Multiple Myeloma Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Targeted Drugs for Multiple Myeloma Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Targeted Drugs for Multiple Myeloma Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Celgene Company Details
    Table 31. Celgene Business Overview
    Table 32. Celgene Targeted Drugs for Multiple Myeloma Product
    Table 33. Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 34. Celgene Recent Development
    Table 35. Exova Company Details
    Table 36. Exova Business Overview
    Table 37. Exova Targeted Drugs for Multiple Myeloma Product
    Table 38. Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 39. Exova Recent Development
    Table 40. Natco Pharma Company Details
    Table 41. Natco Pharma Business Overview
    Table 42. Natco Pharma Targeted Drugs for Multiple Myeloma Product
    Table 43. Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 44. Natco Pharma Recent Development
    Table 45. Intas Pharmaceuticals Company Details
    Table 46. Intas Pharmaceuticals Business Overview
    Table 47. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product
    Table 48. Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 49. Intas Pharmaceuticals Recent Development
    Table 50. Indiabulls Pharmaceutical Company Details
    Table 51. Indiabulls Pharmaceutical Business Overview
    Table 52. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product
    Table 53. Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 54. Indiabulls Pharmaceutical Recent Development
    Table 55. Cipla Company Details
    Table 56. Cipla Business Overview
    Table 57. Cipla Targeted Drugs for Multiple Myeloma Product
    Table 58. Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 59. Cipla Recent Development
    Table 60. Glenmark Pharmaceuticals Company Details
    Table 61. Glenmark Pharmaceuticals Business Overview
    Table 62. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product
    Table 63. Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 64. Glenmark Pharmaceuticals Recent Development
    Table 65. Dr Reddy's Laboratories Company Details
    Table 66. Dr Reddy's Laboratories Business Overview
    Table 67. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product
    Table 68. Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 69. Dr Reddy's Laboratories Recent Development
    Table 70. Qilu Pharmaceutical Company Details
    Table 71. Qilu Pharmaceutical Business Overview
    Table 72. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product
    Table 73. Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 74. Qilu Pharmaceutical Recent Development
    Table 75. Chia Tai-Tianqing Company Details
    Table 76. Chia Tai-Tianqing Business Overview
    Table 77. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product
    Table 78. Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 79. Chia Tai-Tianqing Recent Development
    Table 80. Hanson Pharm Company Details
    Table 81. Hanson Pharm Business Overview
    Table 82. Hanson Pharm Targeted Drugs for Multiple Myeloma Product
    Table 83. Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 84. Hanson Pharm Recent Development
    Table 85. Meidakang Huakang Pharmaceutical Company Details
    Table 86. Meidakang Huakang Pharmaceutical Business Overview
    Table 87. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product
    Table 88. Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 89. Meidakang Huakang Pharmaceutical Recent Development
    Table 90. Shandong Kongfu Pharmaceutical Company Details
    Table 91. Shandong Kongfu Pharmaceutical Business Overview
    Table 92. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product
    Table 93. Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 94. Shandong Kongfu Pharmaceutical Recent Development
    Table 95. J&J Company Details
    Table 96. J&J Business Overview
    Table 97. J&J Targeted Drugs for Multiple Myeloma Product
    Table 98. J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 99. J&J Recent Development
    Table 100. Takeda Company Details
    Table 101. Takeda Business Overview
    Table 102. Takeda Targeted Drugs for Multiple Myeloma Product
    Table 103. Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 104. Takeda Recent Development
    Table 105. Amgen Company Details
    Table 106. Amgen Business Overview
    Table 107. Amgen Targeted Drugs for Multiple Myeloma Product
    Table 108. Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 109. Amgen Recent Development
    Table 110. Bristol Myers Squibb Company Details
    Table 111. Bristol Myers Squibb Business Overview
    Table 112. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product
    Table 113. Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 114. Bristol Myers Squibb Recent Development
    Table 115. Abbvie Company Details
    Table 116. Abbvie Business Overview
    Table 117. Abbvie Targeted Drugs for Multiple Myeloma Product
    Table 118. Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 119. Abbvie Recent Development
    Table 120. Seattle Genetics Company Details
    Table 121. Seattle Genetics Business Overview
    Table 122. Seattle Genetics Targeted Drugs for Multiple Myeloma Product
    Table 123. Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 124. Seattle Genetics Recent Development
    Table 125. Karyopharm Therapeutics Company Details
    Table 126. Karyopharm Therapeutics Business Overview
    Table 127. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product
    Table 128. Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 129. Karyopharm Therapeutics Recent Development
    Table 130. PDL BioPharma Company Details
    Table 131. PDL BioPharma Business Overview
    Table 132. PDL BioPharma Targeted Drugs for Multiple Myeloma Product
    Table 133. PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 134. PDL BioPharma Recent Development
    Table 135. Roche Company Details
    Table 136. Roche Business Overview
    Table 137. Roche Targeted Drugs for Multiple Myeloma Product
    Table 138. Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 139. Roche Recent Development
    Table 140. Sumitomo Company Details
    Table 141. Sumitomo Business Overview
    Table 142. Sumitomo Targeted Drugs for Multiple Myeloma Product
    Table 143. Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 144. Sumitomo Recent Development
    Table 145. Merck Company Details
    Table 146. Merck Business Overview
    Table 147. Merck Targeted Drugs for Multiple Myeloma Product
    Table 148. Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 149. Merck Recent Development
    Table 150. Biogen Company Details
    Table 151. Biogen Business Overview
    Table 152. Biogen Targeted Drugs for Multiple Myeloma Product
    Table 153. Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 154. Biogen Recent Development
    Table 155. Schering-Plough Company Details
    Table 156. Schering-Plough Business Overview
    Table 157. Schering-Plough Targeted Drugs for Multiple Myeloma Product
    Table 158. Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 159. Schering-Plough Recent Development
    Table 160. Glaxo Company Details
    Table 161. Glaxo Business Overview
    Table 162. Glaxo Targeted Drugs for Multiple Myeloma Product
    Table 163. Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 164. Glaxo Recent Development
    Table 165. Chiron Company Details
    Table 166. Chiron Business Overview
    Table 167. Chiron Targeted Drugs for Multiple Myeloma Product
    Table 168. Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 169. Chiron Recent Development
    Table 170. Research Programs/Design for This Report
    Table 171. Key Data Information from Secondary Sources
    Table 172. Key Data Information from Primary Sources
List of Figures
    Figure 1. Targeted Drugs for Multiple Myeloma Product Picture
    Figure 2. Global Targeted Drugs for Multiple Myeloma Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Targeted Drugs for Multiple Myeloma Market Size 2017-2028 (US$ Million)
    Figure 4. United States Targeted Drugs for Multiple Myeloma Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Targeted Drugs for Multiple Myeloma Market Size 2017-2028 (US$ Million)
    Figure 6. United States Targeted Drugs for Multiple Myeloma Market Share in Global 2017-2028
    Figure 7. Targeted Drugs for Multiple Myeloma Report Years Considered
    Figure 8. Product Picture of Immunomodulator
    Figure 9. Product Picture of Proteasome Inhibitors
    Figure 10. Product Picture of Histone Deacetylase Inhibitors (HDACI)
    Figure 11. Product Picture of Monoclonal Antibody
    Figure 12. Product Picture of Other
    Figure 13. Global Targeted Drugs for Multiple Myeloma Market Share by Type in 2022 & 2028
    Figure 14. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Targeted Drugs for Multiple Myeloma Market Share by Type (2017-2028)
    Figure 16. United States Targeted Drugs for Multiple Myeloma Market Share by Type in 2022 & 2028
    Figure 17. United States Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Targeted Drugs for Multiple Myeloma Market Share by Type (2017-2028)
    Figure 19. Product Picture of Hospital
    Figure 20. Product Picture of Drug Center
    Figure 21. Product Picture of Clinic
    Figure 22. Product Picture of Other
    Figure 23. Global Targeted Drugs for Multiple Myeloma Market Share by Application in 2022 & 2028
    Figure 24. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2028) & (US$ Million)
    Figure 25. Global Targeted Drugs for Multiple Myeloma Market Share by Application (2017-2028)
    Figure 26. United States Targeted Drugs for Multiple Myeloma Market Share by Application in 2022 & 2028
    Figure 27. United States Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2028) & (US$ Million)
    Figure 28. United States Targeted Drugs for Multiple Myeloma Market Share by Application (2017-2028)
    Figure 29. North America Targeted Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 30. U.S. Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Canada Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. Europe Targeted Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 33. Germany Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. France Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. U.K. Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Italy Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Russia Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 39. China Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Japan Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. South Korea Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. India Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Australia Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Taiwan Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Indonesia Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Thailand Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Malaysia Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Philippines Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Latin America Targeted Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 50. Mexico Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Brazil Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Argentina Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 54. Turkey Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Saudi Arabia Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. U.A.E Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Celgene Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 58. Exova Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 59. Natco Pharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 60. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 61. Indiabulls Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 62. Cipla Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 63. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 64. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 65. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 66. Chia Tai-Tianqing Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 67. Hanson Pharm Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 68. Meidakang Huakang Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 69. Shandong Kongfu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 70. J&J Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 71. Takeda Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 72. Amgen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 73. Bristol Myers Squibb Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 74. Abbvie Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 75. Seattle Genetics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 76. Karyopharm Therapeutics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 77. PDL BioPharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 78. Roche Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 79. Sumitomo Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 80. Merck Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 81. Biogen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 82. Schering-Plough Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 83. Glaxo Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 84. Chiron Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 85. Bottom-up and Top-down Approaches for This Report
    Figure 86. Data Triangulation
    Figure 87. Key Executives Interviewed